Post by TheBridgeon Mar 25, 2025 11:21am
57 Views
Post# 36508432
One Step Closer
One Step CloserSource: Tech - March 18, 2025
SVNS has provided an update on it's AWKN-SDN-14 programme, a project aimed at developing a next-generation treatment for PTSD.
Concept Life Sciences, which took over from the original research partner Charnwood Discovery when it went into administration, has resumed the research. Three of the six drug candidates have already been synthesisised, and the rest are expected to be completed by May.
Meanwhile, Eurofins Discovery has been carrying out lab tests on the completed drug candidates, and now Evotec - a globally recognised leader in drug discovery - has been brought in to handle the next phase of testing. Its job is to assess how well these compounds trigger the release of key neurotransmitters, including serotonin, dopamine, and noradrenaloine, which are all crucial to PTSD treatment.
Early results from testing have been encouraging, suggesting the programme is on the right track. If all goes to plan, Sovonis and Awakn expect to select a lead drug candidate by the end of September, moving one step closer to bringing a new PTSD treatment to market.